Sood A, Menon P S
Department of Endocrinology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi.
Natl Med J India. 1998 Sep-Oct;11(5):222-5.
The easy availability of growth hormone (GH) in the Indian market has led to its increased use in the management of short stature. However, the therapy is expensive for most families. The possible benefits of such a therapy have to be carefully weighed against the cost and adverse effects. We discuss the drawbacks of relying on data based on predicted height to evaluate the benefits of GH therapy reported in the literature. It is the final adult height which is the true indicator of the efficacy of GH therapy. The only clear indications for GH therapy are short stature associated with GH deficiency and Turner syndrome. Classifying short stature may not be of much help in deciding the utility of GH therapy and the use of auxological criteria alone will increase the burden on society. At present, the use of GH in idiopathic short stature is not indicated in routine clinical practice.
生长激素（GH）在印度市场易于获取，这导致其在矮小症治疗中的使用增加。然而，这种治疗方法对大多数家庭来说费用高昂。必须仔细权衡这种治疗可能带来的益处与成本及不良反应。我们讨论了依赖基于预测身高的数据来评估文献中报道的生长激素治疗益处的弊端。最终的成人身高才是生长激素治疗疗效的真正指标。生长激素治疗唯一明确的指征是与生长激素缺乏和特纳综合征相关的矮小症。对矮小症进行分类在决定生长激素治疗的效用方面可能帮助不大，仅使用体格学标准会增加社会负担。目前，在常规临床实践中不建议对特发性矮小症使用生长激素。
